Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer

Abstract

Aim: To assess the efficacy and safety of combination of PD-1 inhibitors, recombinant human endostatin (Rh-endostatin) and chemotherapy as first-line treatment for advanced non-small-cell lung cancer (NSCLC). Methods: A total of 100 patients with advanced NSCLC were retrospectively reviewed and analyzed (58 in the group receiving PD-1 inhibitors plus Rh-endostatin and chemotherapy; 42 in the group receiving Rh-endostatin and chemotherapy). The primary end point was progression-free survival. Results: Patients in the group receiving PD-1 inhibitors plus Rh-endostatin and chemotherapy had significantly improved progression-free survival (10.2 vs 6.5months; p<0.001) and objective response rate (67.2 vs 42.9%; p=0.015), with acceptable toxicity. Conclusion: Our study showed the superiority of combination therapy of PD-1 inhibitors and Rh-endostatin as first-line treatment for advanced NSCLC.

Plain language summary

This study retrospectively analyzed the effectiveness and safety of PD-1 inhibitors combined with recombinant human endostatin (Rh-endostatin) and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. Among them, 58 patients received a PD-1 inhibitor combined with Rh-endostatin and chemotherapy (treatment group), and 42 patients received Rh-endostatin combined with chemotherapy (control group). Patients in the treatment group had a significantly improved objective response rate (67.2 vs 42.9%; p=0.015) and prolonged survival without their disease getting worse (10.2 vs 6.5months; p<0.001). No significant differences were found in the adverse events between the two groups.

Tweetable abstract

Study showing superiority of combination therapy of PD-1 inhibitors combined with Rh-endostatin as first-line treatment for advanced non-small-cell lung cancer in terms of objective response rate and progression-free survival, making it a promising treatment modality for this population.

Keywords::

• angiogenesis inhibitors
• immune checkpoint inhibitors
• non-small-cell lung cancer
• tumor microenvironments

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.tandfonline.com/doi/suppl/10.2217/fon-2022-0861

Author contributions

L Chen and Z Lu contributed to the conception and design of the study. S Li, P Zhong, X Zhu and S Peng collected the data and organized the database. S Fu, K Shang, Y Liu and G Tu performed the statistical analysis. S Fu and H Huang wrote the first draft of the manuscript and completed the final review of the manuscript. All authors contributed to manuscript revision, reading and approving the submitted version.

Financial & competing interests disclosure

This study was funded by the National Natural Science Foundation for Young Scientists of China (grant no. 82103339) and the Medical Scientific Research Foundation from the Health Commission of Jiangxi Province, China (no. 202210473). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

Additional information

Funding

This study was funded by the National Natural Science Foundation for Young Scientists of China (grant no. 82103339) and the Medical Scientific Research Foundation from the Health Commission of Jiangxi Province, China (no. 202210473). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.